SK279196B6 - 2-metyl-10-(4-metyl-1-piperazinyl)-4h-tieno-[2,3-b - Google Patents

2-metyl-10-(4-metyl-1-piperazinyl)-4h-tieno-[2,3-b Download PDF

Info

Publication number: SK279196B6
Authority: SK; Slovakia
Prior art keywords: methyl; compound; preparation; thieno; benzodiazepine
Prior art date: 1990-04-25

Application number

SK1168-91A

Other languages

English (en)

Slovak (sk)

Inventor

Jiban K. Chakrabarti

Terrence M. Hotten

David E. Tupper

Original Assignee

Eli Lilly And Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-25

Filing date

1991-04-24

Publication date

1998-07-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10674942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK279196(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1991-04-24 Application filed by Eli Lilly And Company Limited filed Critical Eli Lilly And Company Limited

1998-07-08 Publication of SK279196B6 publication Critical patent/SK279196B6/sk

Links

238000002360 preparation method Methods 0.000 title claims abstract description 11
238000000034 method Methods 0.000 title claims abstract description 7
239000008177 pharmaceutical agent Substances 0.000 title abstract 2
150000003839 salts Chemical class 0.000 claims abstract description 19
239000002253 acid Substances 0.000 claims abstract description 14
150000001875 compounds Chemical class 0.000 claims description 78
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 10
239000002775 capsule Substances 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 6
208000015114 central nervous system disease Diseases 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
210000003169 central nervous system Anatomy 0.000 abstract description 3
208000035475 disorder Diseases 0.000 abstract description 2
230000000694 effects Effects 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
239000000203 mixture Substances 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
238000006243 chemical reaction Methods 0.000 description 13
239000002904 solvent Substances 0.000 description 13
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 11
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
229940079593 drug Drugs 0.000 description 10
239000000243 solution Substances 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
229920002472 Starch Polymers 0.000 description 8
239000000543 intermediate Substances 0.000 description 8
201000000980 schizophrenia Diseases 0.000 description 8
235000019698 starch Nutrition 0.000 description 8
239000004480 active ingredient Substances 0.000 description 7
239000008107 starch Substances 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
JBHUBOISLBWHAR-UHFFFAOYSA-N Flumezapine Chemical compound C1CN(C)CCN1C1=NC2=CC(F)=CC=C2NC2=C1C=C(C)S2 JBHUBOISLBWHAR-UHFFFAOYSA-N 0.000 description 6
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000000164 antipsychotic agent Substances 0.000 description 6
229950005785 flumezapine Drugs 0.000 description 6
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 6
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
201000010099 disease Diseases 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
239000007787 solid Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
230000002411 adverse Effects 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
150000001409 amidines Chemical class 0.000 description 4
239000003054 catalyst Substances 0.000 description 4
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
-1 inorganic acids Chemical class 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
229920001296 polysiloxane Polymers 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
238000006798 ring closing metathesis reaction Methods 0.000 description 4
239000012312 sodium hydride Substances 0.000 description 4
229910000104 sodium hydride Inorganic materials 0.000 description 4
238000003756 stirring Methods 0.000 description 4
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 3
208000012661 Dyskinesia Diseases 0.000 description 3
208000028017 Psychotic disease Diseases 0.000 description 3
239000013543 active substance Substances 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
230000000561 anti-psychotic effect Effects 0.000 description 3
229940005529 antipsychotics Drugs 0.000 description 3
239000002585 base Substances 0.000 description 3
238000009227 behaviour therapy Methods 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
208000010118 dystonia Diseases 0.000 description 3
125000004185 ester group Chemical group 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
150000003573 thiols Chemical class 0.000 description 3
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
208000009132 Catalepsy Diseases 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
208000014094 Dystonic disease Diseases 0.000 description 2
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
206010047853 Waxy flexibility Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
229960004046 apomorphine Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
238000004820 blood count Methods 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
238000009833 condensation Methods 0.000 description 2
230000005494 condensation Effects 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000000265 leukocyte Anatomy 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
GHPDMFBHITXJAZ-UHFFFAOYSA-N methyl 2-amino-5-methylthiophene-3-carboxylate Chemical compound COC(=O)C=1C=C(C)SC=1N GHPDMFBHITXJAZ-UHFFFAOYSA-N 0.000 description 2
ATSANGLCFQGIMM-UHFFFAOYSA-N methyl 5-methyl-2-(2-nitroanilino)thiophene-3-carboxylate Chemical compound C1=C(C)SC(NC=2C(=CC=CC=2)[N+]([O-])=O)=C1C(=O)OC ATSANGLCFQGIMM-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000003176 neuroleptic agent Substances 0.000 description 2
150000002828 nitro derivatives Chemical class 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
230000002085 persistent effect Effects 0.000 description 2
229920001021 polysulfide Polymers 0.000 description 2
239000005077 polysulfide Substances 0.000 description 2
150000008117 polysulfides Polymers 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229950001675 spiperone Drugs 0.000 description 2
239000001119 stannous chloride Substances 0.000 description 2
235000011150 stannous chloride Nutrition 0.000 description 2
GLBQVJGBPFPMMV-UHFFFAOYSA-N sulfilimine Chemical class S=N GLBQVJGBPFPMMV-UHFFFAOYSA-N 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
229930192474 thiophene Natural products 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
UPLLQJUZZIYKHI-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;2-oxobutanedioic acid Chemical compound OC(=O)CC(=O)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O UPLLQJUZZIYKHI-DFWYDOINSA-N 0.000 description 1
QJKHENCJQIAEBH-UHFFFAOYSA-N (Methylsulfinyl)methanide Chemical compound CS([CH2-])=O QJKHENCJQIAEBH-UHFFFAOYSA-N 0.000 description 1
BFCFYVKQTRLZHA-UHFFFAOYSA-N 1-chloro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1Cl BFCFYVKQTRLZHA-UHFFFAOYSA-N 0.000 description 1
VMLRGLWEZFXINP-UHFFFAOYSA-N 1h-1,5-benzodiazepin-5-ium;chloride Chemical compound Cl.N1C=CC=NC2=CC=CC=C12 VMLRGLWEZFXINP-UHFFFAOYSA-N 0.000 description 1
YGXADLPRHBRTPG-UHFFFAOYSA-N 2-amino-5-methylthiophene-3-carbonitrile Chemical compound CC1=CC(C#N)=C(N)S1 YGXADLPRHBRTPG-UHFFFAOYSA-N 0.000 description 1
JXPDNDHCMMOJPC-UHFFFAOYSA-N 2-hydroxybutanedinitrile Chemical compound N#CC(O)CC#N JXPDNDHCMMOJPC-UHFFFAOYSA-N 0.000 description 1
FDWMAKNNNPSUTL-UHFFFAOYSA-N 2-methyl-10H-thieno[2,3-b][1,5]benzodiazepin-4-amine hydrochloride Chemical compound Cl.N1C2=CC=CC=C2N=C(N)C2=C1SC(C)=C2 FDWMAKNNNPSUTL-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
NPXUFPFFHANGDL-UHFFFAOYSA-N 5-methyl-2-(2-nitroanilino)thiophene-3-carbonitrile Chemical compound S1C(C)=CC(C#N)=C1NC1=CC=CC=C1[N+]([O-])=O NPXUFPFFHANGDL-UHFFFAOYSA-N 0.000 description 1
201000010000 Agranulocytosis Diseases 0.000 description 1
206010001540 Akathisia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
101150049660 DRD2 gene Proteins 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
206010017600 Galactorrhoea Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010026749 Mania Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
102000003946 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
208000001431 Psychomotor Agitation Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229910003074 TiCl4 Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
102000003929 Transaminases Human genes 0.000 description 1
108090000340 Transaminases Proteins 0.000 description 1
229910021550 Vanadium Chloride Inorganic materials 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
HIGRAKVNKLCVCA-UHFFFAOYSA-N alumine Chemical compound C1=CC=[Al]C=C1 HIGRAKVNKLCVCA-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000001022 anti-muscarinic effect Effects 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
229960004170 clozapine Drugs 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000010908 decantation Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
JSYGRUBHOCKMGQ-UHFFFAOYSA-N dichloramine Chemical compound ClNCl JSYGRUBHOCKMGQ-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
201000000079 gynecomastia Diseases 0.000 description 1
PDPJQWYGJJBYLF-UHFFFAOYSA-J hafnium tetrachloride Chemical compound Cl[Hf](Cl)(Cl)Cl PDPJQWYGJJBYLF-UHFFFAOYSA-J 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
150000002466 imines Chemical group 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910001510 metal chloride Inorganic materials 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
ANGDWNBGPBMQHW-UHFFFAOYSA-N methyl cyanoacetate Chemical compound COC(=O)CC#N ANGDWNBGPBMQHW-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical compound O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
RPESBQCJGHJMTK-UHFFFAOYSA-I pentachlorovanadium Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[V+5] RPESBQCJGHJMTK-UHFFFAOYSA-I 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
239000012056 semi-solid material Substances 0.000 description 1
210000002265 sensory receptor cell Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000000454 talc Substances 0.000 description 1
FKHIFSZMMVMEQY-UHFFFAOYSA-N talc Chemical compound [Mg+2].[O-][Si]([O-])=O FKHIFSZMMVMEQY-UHFFFAOYSA-N 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
150000005621 tetraalkylammonium salts Chemical class 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
125000001391 thioamide group Chemical group 0.000 description 1
150000003556 thioamides Chemical class 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
DUNKXUFBGCUVQW-UHFFFAOYSA-J zirconium tetrachloride Chemical compound Cl[Zr](Cl)(Cl)Cl DUNKXUFBGCUVQW-UHFFFAOYSA-J 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Anesthesiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Plural Heterocyclic Compounds (AREA)
Cephalosporin Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)

SK1168-91A 1990-04-25 1991-04-24 2-metyl-10-(4-metyl-1-piperazinyl)-4h-tieno-[2,3-b SK279196B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909009229A GB9009229D0 (en)	1990-04-25	1990-04-25	Pharmaceutical compounds

Publications (1)

Publication Number	Publication Date
SK279196B6 true SK279196B6 (sk)	1998-07-08

Family

ID=10674942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1168-91A SK279196B6 (sk)	1990-04-25	1991-04-24	2-metyl-10-(4-metyl-1-piperazinyl)-4h-tieno-[2,3-b

Country Status (33)

Country	Link
EP (1)	EP0454436B1 (fr)
JP (1)	JP2527860B2 (fr)
KR (1)	KR100195566B1 (fr)
CN (1)	CN1028429C (fr)
AT (1)	ATE127804T1 (fr)
AU (1)	AU643267B2 (fr)
BG (1)	BG61710B2 (fr)
CA (1)	CA2041113C (fr)
CY (1)	CY1900A (fr)
CZ (1)	CZ279937B6 (fr)
DE (3)	DE69112895T4 (fr)
DK (1)	DK0454436T3 (fr)
ES (1)	ES2078440T3 (fr)
FI (1)	FI101379B1 (fr)
GB (1)	GB9009229D0 (fr)
GE (1)	GEP20032965B (fr)
GR (1)	GR3017877T3 (fr)
HK (1)	HK87596A (fr)
HU (2)	HU212416B (fr)
IE (1)	IE68401B1 (fr)
IL (2)	IL97912A (fr)
LU (2)	LU90009I2 (fr)
LV (1)	LV10262B (fr)
MX (1)	MX173791B (fr)
NL (2)	NL970015I2 (fr)
NO (3)	NO178766C (fr)
NZ (1)	NZ237932A (fr)
PT (1)	PT97446B (fr)
RU (1)	RU2043992C1 (fr)
SI (1)	SI9110739A (fr)
SK (1)	SK279196B6 (fr)
YU (1)	YU48049B (fr)
ZA (1)	ZA913085B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5627178A (en) *	1991-04-23	1997-05-06	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5817657A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Psychoactive substance disorders
US5817655A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Methods of treatment using a thieno-benzodiazepine
US5817656A (en) *	1991-04-23	1998-10-06	Eli Lilly And Company	Mental disorders
DK0582368T3 (da) *	1992-05-29	2001-02-05	Lilly Co Eli	Thienobenzodiazepinderivater til behandling af forstyrrelser i centralnervesystemet
US6034078A (en) *	1992-05-29	2000-03-07	Eli Lilly And Company Limited	Thienobenzodiazepine compounds
JP3274579B2 (ja) *	1995-01-12	2002-04-15	住友製薬株式会社	脳血管障害に伴う精神症候治療剤
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) *	1995-03-24	2008-11-10	Lilly Co Eli	Process for preparing olanzapine
IL117612A0 (en) *	1995-03-24	1996-07-23	Lilly Co Eli	Granule formulation for olanzapine
CR5278A (es) *	1995-03-24	1996-07-04	Lilly Co Eli	Formulacion oral de 2-metil-tieno-benzodiacepina
CN1131035C (zh) *	1995-05-30	2003-12-17	伊莱利利公司	治疗识别机能障碍的方法
US6506746B2 (en)	1995-05-30	2003-01-14	Eli Lilly And Company	Method for treating cognitive dysfunction
ES2180643T3 (es) *	1995-05-30	2003-02-16	Lilly Co Eli	Procedimiento para tratar la disfuncion cognitiva.
US5891461A (en) *	1995-09-14	1999-04-06	Cygnus, Inc.	Transdermal administration of olanzapine
JP2000502346A (ja) *	1995-12-21	2000-02-29	イーライ・リリー・アンド・カンパニー	皮膚炎の処置方法
UA57727C2 (uk) *	1996-03-11	2003-07-15	Елі Ліллі Енд Компані	Спосіб лікування надмірної агресивності
CZ299247B6 (cs) *	1996-09-23	2008-05-28	Eli Lilly And Company	Olanzapin dihydrát D
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
DE69816102D1 (de)	1997-09-02	2003-08-07	Mitsubishi Pharma Corp	Kondensierte thiophenderivate und ihre medizinische anwendung
GB9718986D0 (en) *	1997-09-09	1997-11-12	Danbiosyst Uk	Controlled release microsphere delivery system
KR100537713B1 (ko) *	1997-09-30	2005-12-20	일라이 릴리 앤드 캄파니	2-메틸-티에노-벤조디아제핀 제제
FR2802101B1 (fr)	1999-12-10	2003-02-28	Aventis Pharma Sa	Association de cymemazine et d'un neuroleptique atypique
SK2502003A3 (en)	2000-08-31	2004-03-02	Reddys Lab Ltd Dr	Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
RU2185383C1 (ru) *	2001-05-22	2002-07-20	Институт молекулярной генетики РАН	ВЫСОКОМЕЧЕННЫЙ ТРИТИЕМ 2-МЕТИЛ-4-(4-МЕТИЛ-1-ПИПЕРАЗИНИЛ)-10Н-ТИЕНО[2,3-b][1,5]БЕНЗОДИАЗЕПИН
CA2471341C (fr) *	2001-12-24	2012-01-24	Sun Pharmaceutical Industries Limited	Forme cristalline de 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
PL196814B1 (pl) *	2002-05-17	2008-02-29	Inst Farmaceutyczny	Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en)	2002-05-31	2007-11-20	Sandoz, Inc.	Process of preparation of olanzapine form I
US20040063694A1 (en) *	2002-06-05	2004-04-01	Browder Monte R.	Compound useful for the treatment of CNS disorders
PL199016B1 (pl)	2002-06-20	2008-08-29	Adamed Sp Z Oo	Sposób wytwarzania olanzapiny
SI21303A (sl)	2002-10-18	2004-04-30	Krka, Tovarna Zdravil, D.D.,, Novo Mesto	Farmacevtska formulacija olanzapina
PL202856B1 (pl) *	2002-12-20	2009-07-31	Adamed Spo & Lstrok Ka Z Ogran	Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
DE10301923B3 (de) *	2003-01-17	2004-09-16	Krka Tovarna Zdravil, D.D.	Verfahren und Zwischenprodukte zur Herstellung von Olanzapin
HU226410B1 (en) *	2003-04-22	2008-11-28	Egis Gyogyszergyar Nyilvanosan	Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
DE602004014264D1 (de)	2003-12-22	2008-07-17	Teva Pharma	Verfahren zur herstellung von olanzapin
AR047461A1 (es) *	2004-01-27	2006-01-18	Synthon Bv	Formacion, purificacion y uso de n-formilolanzapina
ATE504588T1 (de)	2004-01-27	2011-04-15	Synthon Bv	Stabile salze von olanzapin
AR048272A1 (es) *	2004-03-18	2006-04-12	Lek Pharmaceuticals	Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
ES2253091B1 (es) *	2004-07-27	2007-02-01	Inke, S.A.	Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) *	2004-07-28	2006-02-28	Krka, Tovarna Zdravil, D.D., Novo Mesto	Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
AU2005307797B2 (en) *	2004-11-16	2011-06-02	Alkermes Pharma Ireland Limited	Injectable nanoparticulate olanzapine formulations
PL198589B1 (pl)	2004-11-22	2008-06-30	Adamed Sp Z Oo	Sposób wytwarzania N-demetyloolanzapiny
PL1838716T3 (pl)	2005-01-05	2011-09-30	Lilly Co Eli	Dihydrat embonianu olanzapiny
HUP0501046A2 (en) *	2005-11-11	2007-08-28	Egis Gyogyszergyar Nyilvanosan	Process for the preparation of olanzapine
US7834176B2 (en)	2006-01-26	2010-11-16	Sandoz Ag	Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CN100383144C (zh) *	2006-09-11	2008-04-23	杭州盛美医药科技开发有限公司	一种奥氮平的中间体及其制备与应用
CL2007002807A1 (es) *	2006-09-29	2008-04-11	Synthon Bv	Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
PL381564A1 (pl)	2007-01-22	2008-08-04	Koźluk Tomasz Nobilus Ent	Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (fr)	2007-06-22	2008-12-22	Apotex Pharmachem Inc.	Procedes ameliores pour la synthese de l'olanzapine
CN101168544B (zh) *	2007-11-16	2010-11-17	西南合成制药股份有限公司	奥氮平的制备工艺
CN101735239B (zh) *	2008-11-06	2011-08-31	齐鲁制药有限公司	一种无水奥氮平晶型ii的制备方法
EP2292624A1 (fr)	2009-07-20	2011-03-09	LEK Pharmaceuticals d.d.	Processus de purification d'olanzapine
CN102532158A (zh) *	2010-12-17	2012-07-04	北大方正集团有限公司	一种合成奥氮平的方法
EP2486913A1 (fr)	2011-02-14	2012-08-15	Labtec GmbH	Formulation de film oral à désintégration rapide pour olanzapine
WO2012153347A2 (fr)	2011-05-04	2012-11-15	Zentiva K.S.	Composition pharmaceutique d'olanzapine de forme 1 à administration par voie orale
CN102225941B (zh) *	2011-06-01	2013-11-27	宁波人健医药化工有限公司	抗精神病药奥氮平的制备方法
WO2013066280A1 (fr) *	2011-10-31	2013-05-10	Mahmut Bilgic	Formulations antipsychotiques hydrosolubles
JP5934004B2 (ja) *	2012-03-22	2016-06-15	株式会社トクヤマ	結晶構造を有する４−アミノ−２−メチル−１０Ｈ−チエノ〔２，３−ｂ〕〔１，５〕ベンゾジアゼピン塩酸塩水和物及びその製造方法
US20150216206A1 (en)	2012-07-31	2015-08-06	Sanovel Hayvan Sagligi Urunleri Sanayi Ve Ticaret Anonim Sirketi	Method for increasing meat and milk production
EP2879518A1 (fr)	2012-07-31	2015-06-10	Sanovel Hayvan Sagligi Ürünleri Sanayi ve Ticaret A.S.	Utilisation d'olanzapine chez des animaux
JP6042153B2 (ja) *	2012-09-26	2016-12-14	株式会社トクヤマ	オランザピンの製造方法
KR101641902B1 (ko)	2015-06-24	2016-07-22	주식회사 네이처센스 농업회사법인	스트레스의 완화용 조성물
CN106265541A (zh) *	2016-08-31	2017-01-04	安徽省润生医药股份有限公司	一种注射用奥氮平及其制备方法
CN111004210A (zh) *	2019-10-23	2020-04-14	中山大学	化合物单晶及其制备方法
WO2025056094A1 (fr) *	2023-09-15	2025-03-20	广州帝奇医药技术有限公司	Préparation lyophilisée, injection, et procédé de préparation associé

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU629879A3 (ru)	1974-11-26	1978-10-25	Лилли Индастриз Лимитед, (Фирма)	Способ получени тиено(1,5) бензодиазепинов или их солей
US3953430A (en) *	1975-02-24	1976-04-27	American Cyanamid Company	Substituted benzodiazepin-10-ones and method of use
GB1533236A (en) *	1975-11-24	1978-11-22	Lilly Industries Ltd	Thieno(1,5)benzodiazepine intermediates
GB1577743A (en) *	1977-05-17	1980-10-29	Lilly Industries Ltd	Benzodiazepine derivatives

1990
- 1990-04-25 GB GB909009229A patent/GB9009229D0/en active Pending
1991
- 1991-04-22 IL IL9791291A patent/IL97912A/en not_active IP Right Cessation
- 1991-04-22 AU AU75186/91A patent/AU643267B2/en not_active Expired
- 1991-04-23 PT PT97446A patent/PT97446B/pt not_active IP Right Cessation
- 1991-04-23 IE IE134891A patent/IE68401B1/en not_active IP Right Cessation
- 1991-04-24 ZA ZA913085A patent/ZA913085B/xx unknown
- 1991-04-24 YU YU73991A patent/YU48049B/sh unknown
- 1991-04-24 NZ NZ237932A patent/NZ237932A/en unknown
- 1991-04-24 MX MX2550291A patent/MX173791B/es unknown
- 1991-04-24 HU HU911372A patent/HU212416B/hu active IP Right Revival
- 1991-04-24 DE DE69112895T patent/DE69112895T4/de not_active Expired - Lifetime
- 1991-04-24 CZ CS911168A patent/CZ279937B6/cs not_active IP Right Cessation
- 1991-04-24 DE DE69112895A patent/DE69112895D1/de not_active Expired - Lifetime
- 1991-04-24 AT AT91303679T patent/ATE127804T1/de active
- 1991-04-24 ES ES91303679T patent/ES2078440T3/es not_active Expired - Lifetime
- 1991-04-24 FI FI911986A patent/FI101379B1/fi active Protection Beyond IP Right Term
- 1991-04-24 CN CN91103346A patent/CN1028429C/zh not_active Expired - Lifetime
- 1991-04-24 SI SI9110739A patent/SI9110739A/sl unknown
- 1991-04-24 NO NO911624A patent/NO178766C/no not_active IP Right Cessation
- 1991-04-24 JP JP3228215A patent/JP2527860B2/ja not_active Expired - Lifetime
- 1991-04-24 EP EP91303679A patent/EP0454436B1/fr not_active Expired - Lifetime
- 1991-04-24 DK DK91303679.4T patent/DK0454436T3/da active
- 1991-04-24 LU LU90009C patent/LU90009I2/fr unknown
- 1991-04-24 SK SK1168-91A patent/SK279196B6/sk not_active IP Right Cessation
- 1991-04-24 KR KR1019910006544A patent/KR100195566B1/ko not_active Expired - Lifetime
- 1991-04-24 CY CY190091A patent/CY1900A/xx unknown
- 1991-04-24 DE DE1996175046 patent/DE19675046I2/de active Active
- 1991-04-24 CA CA002041113A patent/CA2041113C/fr not_active Expired - Lifetime
1992
- 1992-09-25 RU SU925052762A patent/RU2043992C1/ru active
1993
- 1993-06-08 LV LVP-93-517A patent/LV10262B/xx unknown
1994
- 1994-02-02 BG BG098434A patent/BG61710B2/bg unknown
1995
- 1995-02-08 IL IL11257595A patent/IL112575A0/xx unknown
- 1995-06-22 HU HU95P/P00335P patent/HU211575A9/hu unknown
- 1995-10-25 GR GR950402982T patent/GR3017877T3/el unknown
1996
- 1996-05-16 HK HK87596A patent/HK87596A/en not_active IP Right Cessation
1997
- 1997-03-21 NL NL970015C patent/NL970015I2/nl unknown
- 1997-05-12 NO NO1997005C patent/NO1997005I1/no unknown
2001
- 2001-10-18 GE GEAP20016159A patent/GEP20032965B/en unknown
- 2001-12-21 LU LU90869C patent/LU90869I2/fr unknown
- 2001-12-28 NL NL300078C patent/NL300078I1/nl unknown
- 2001-12-28 NO NO2001028C patent/NO2001028I1/no unknown

Also Published As

Publication number	Publication date
HU911372D0 (en)	1991-10-28
HU211575A9 (en)	1995-12-28
MX173791B (es)	1994-03-25
NO178766C (no)	1996-05-29
NO178766B (no)	1996-02-19
LV10262A (lv)	1994-10-20
GR3017877T3 (en)	1996-01-31
ATE127804T1 (de)	1995-09-15
IE911348A1 (en)	1991-11-06
CS9101168A2 (en)	1991-12-17
NO911624D0 (no)	1991-04-24
DE19675046I2 (de)	2001-05-23
KR910018387A (ko)	1991-11-30
GEP20032965B (en)	2003-05-12
NL970015I1 (nl)	1997-06-02
IL112575A0 (en)	1995-05-26
MX25502A (es)	1993-10-01
CN1028429C (zh)	1995-05-17
CA2041113A1 (fr)	1991-10-26
HK87596A (en)	1996-05-24
JP2527860B2 (ja)	1996-08-28
NO911624L (no)	1991-10-28
IL97912A (en)	1995-10-31
HUT60503A (en)	1992-09-28
KR100195566B1 (ko)	1999-06-15
AU643267B2 (en)	1993-11-11
FI101379B (fi)	1998-06-15
LU90869I2 (fr)	2002-02-21
JPH0789965A (ja)	1995-04-04
FI911986A0 (fi)	1991-04-24
IE68401B1 (en)	1996-06-12
SI9110739A (en)	1997-10-31
HU212416B (en)	1996-06-28
NO1997005I1 (no)	1997-05-12
NZ237932A (en)	1993-08-26
NL300078I1 (nl)	2002-03-01
PT97446B (pt)	1997-07-31
DK0454436T3 (da)	1995-11-13
DE69112895T4 (de)	2009-11-12
CA2041113C (fr)	1998-07-14
LV10262B (en)	1995-04-20
GB9009229D0 (en)	1990-06-20
RU2043992C1 (ru)	1995-09-20
YU48049B (sh)	1996-10-18
CN1056693A (zh)	1991-12-04
ZA913085B (en)	1992-12-30
FI101379B1 (fi)	1998-06-15
AU7518691A (en)	1991-11-07
DE69112895D1 (de)	1995-10-19
BG61710B2 (bg)	1998-03-31
ES2078440T3 (es)	1995-12-16
EP0454436A1 (fr)	1991-10-30
NL970015I2 (nl)	1997-09-01
EP0454436B1 (fr)	1995-09-13
LU90009I2 (fr)	1997-01-31
CZ279937B6 (cs)	1995-09-13
NO2001028I1 (no)	2002-01-28
FI911986L (fi)	1991-10-26
PT97446A (pt)	1992-01-31
YU73991A (sh)	1994-01-20
CY1900A (en)	1991-04-24
DE69112895T2 (de)	1996-03-07
IL97912A0 (en)	1992-06-21

Legal Events

Date	Code	Title	Description
2011-06-06	MK4A	Patent expired	Expiry date: 20110424

Publication	Publication Date	Title
SK279196B6 (sk)	1998-07-08	2-metyl-10-(4-metyl-1-piperazinyl)-4h-tieno-[2,3-b
US5229382A (en)	1993-07-20	2-methyl-thieno-benzodiazepine
US6008216A (en)	1999-12-28	Process for preparing 2-methyl-thieno-benzodiazepine
US5605897A (en)	1997-02-25	2-methyl-thieno-benzodiazepine
RU2125574C1 (ru)	1999-01-27	Тиенобензодиазепины или их фармацевтически приемлемые соли, способ их получения и фармацевтическая композиция
US5817656A (en)	1998-10-06	Mental disorders
DE69630209T2 (de)	2004-08-19	Bicyclische benzazepin-derivate als vasopressin-antagonisten
US5817655A (en)	1998-10-06	Methods of treatment using a thieno-benzodiazepine
US5817657A (en)	1998-10-06	Psychoactive substance disorders
GB2120662A (en)	1983-12-07	New azepinoindoles, their production and pharmaceutical compositions containing them
US5051516A (en)	1991-09-24	Benzodiazepine compounds and their use as pharmaceuticals
US6211364B1 (en)	2001-04-03	Process for preparing indane-like compounds
CA2350560C (fr)	2006-10-31	Nouveaux types de composes de pyridazinone condenses
US4816474A (en)	1989-03-28	Amino substituted thienothiopyran derivatives, composition containing them, and method of using them to stimulate presynaptic dopamine receptors
SA95160196B1 (ar)	2005-12-21	مركبات صيدلانية
NZ240501A (en)	1992-05-26	4- or 5-(2-nitroanilino)thiazole derivatives